For example, melanoma is one of the most
drug-resistant cancers and the standard treatment options used
for metastatic melanoma are interferon and dacarbazine, which
have not shown a good therapeutic outcome. Some recent pre-clinical
studies have suggested that polyphenols in combination with
standard treatment options may be a viable approach for melanoma. Further, Yang et al. demonstrated that resveratrol is
an APE/Ref-1 inhibitor and enhances the therapeutic efficacy of
dacarbazine for melanoma. Thus, it appears that resveratrol
may have bright prospects as an adjuvant therapy for melanoma
management.